N
19.94
-0.46 (-2.25%)
| Penutupan Terdahulu | 20.40 |
| Buka | 20.28 |
| Jumlah Dagangan | 62,332 |
| Purata Dagangan (3B) | 220,195 |
| Modal Pasaran | 308,866,624 |
| Harga / Jualan (P/S) | 438.73 |
| Harga / Buku (P/B) | 1.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| Margin Operasi (TTM) | -9,701.19% |
| EPS Cair (TTM) | -4.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.01% |
| Nisbah Semasa (MRQ) | 21.03 |
| Aliran Tunai Operasi (OCF TTM) | -69.73 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.39 M |
| Pulangan Atas Aset (ROA TTM) | -21.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Neurogene Inc. | Menaik | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.13 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 9.28% |
| % Dimiliki oleh Institusi | 115.82% |
| Julat 52 Minggu | ||
| Median | 70.00 (251.05%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2025 | 70.00 (251.05%) | Beli | 26.49 |
| 31 Oct 2025 | 65.00 (225.98%) | Beli | 34.26 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 13 Nov 2025 | Pengumuman | Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates |
| 12 Nov 2025 | Pengumuman | Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome |
| 06 Nov 2025 | Pengumuman | Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome |
| 05 Nov 2025 | Pengumuman | Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 09 Oct 2025 | Pengumuman | Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 |
| 08 Oct 2025 | Pengumuman | Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference |
| 03 Oct 2025 | Pengumuman | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |